Smedts F, Ramaekers F, Troyanovsky S, Pruszczynski M, Link M, Lane B, Leigh I, Schijf C, Vooijs P
Department of Pathology, University Hospital Nijmegen, The Netherlands.
Am J Pathol. 1992 Aug;141(2):497-511.
Using a panel of 21 monoclonal and 2 polyclonal keratin antibodies, capable of detecting separately 11 subtypes of their epithelial intermediate filament proteins at the single cell level, we investigated keratin expression in 16 squamous cell carcinomas, 9 adenocarcinomas, and 3 adenosquamous carcinomas of the human uterine cervix. The keratin phenotype of the keratinizing squamous cell carcinoma was found to be most complex comprising keratins 4, 5, 6, 8, 13, 14, 16, 17, 18, 19, and usually keratin 10. The nonkeratinizing variety of the squamous cell carcinoma expressed keratins 6, 14, 17, and 19 in all cases, usually 4, 5, 7, 8, and 18, and sometimes keratins 10, 13, and 16. Adenocarcinomas displayed a less complex keratin expression pattern comprising keratins 7, 8, 17, 18, and 19, while keratin 14 was often present and keratins 4, 5, 10 and 13 were sporadically found in individual cells in a few cases. These keratin phenotypes may be useful in differential diagnostic considerations when distinguishing between keratinizing and nonkeratinizing carcinomas (using keratin 10, 13, and 16 antibodies), and also in the distinction between nonkeratinizing carcinomas and poorly differentiated adenocarcinomas, which do not express keratins 5 and 6. Keratin 17 may also be useful in distinguishing carcinomas of the cervix from those of the colon and also from mesotheliomas. Furthermore the presence of keratin 17 in a CIN I, II, or III lesion may indicate progressive potential while its absence could be indicative of a regressive behavior. Because most carcinomas express keratins 8, 14, 17, 18, and 19, we propose that this expression pattern reflects the origin of cervical cancer from a common progenitor cell, i.e., the endocervical reserve cell that has been shown to express keratins 5, 8, 14, 17, 18, and 19.
我们使用一组21种单克隆抗体和2种多克隆角蛋白抗体，这些抗体能够在单细胞水平分别检测11种上皮中间丝蛋白亚型，研究了16例人子宫颈鳞状细胞癌、9例腺癌和3例腺鳞癌中的角蛋白表达情况。发现角化型鳞状细胞癌的角蛋白表型最为复杂，包括角蛋白4、5、6、8、13、14、16、17、18、19，通常还有角蛋白10。鳞状细胞癌的非角化型在所有病例中均表达角蛋白6、14、17和19，通常还有4、5、7、8和18，有时还表达角蛋白10、13和16。腺癌显示出较简单的角蛋白表达模式，包括角蛋白7、8、17、18和19，而角蛋白14常存在，在少数病例中个别细胞偶尔会发现角蛋白4、5、10和13。这些角蛋白表型在鉴别角化型和非角化型癌（使用角蛋白10、13和16抗体）时，以及在鉴别不表达角蛋白5和6的非角化型癌和低分化腺癌时，可能有助于鉴别诊断。角蛋白17在区分子宫颈癌与结肠癌以及间皮瘤时也可能有用。此外，CIN I、II或III病变中角蛋白17的存在可能表明有进展潜能，而其缺失可能表明有消退行为。由于大多数癌表达角蛋白8、14、17、18和19，我们认为这种表达模式反映了宫颈癌起源于一个共同的祖细胞，即已被证明表达角蛋白5、8、14、17、18和19的宫颈储备细胞。
